| __timestamp | Bio-Techne Corporation | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 22622695 |
| Thursday, January 1, 2015 | 144969000 | 24863028 |
| Friday, January 1, 2016 | 162364000 | 21351001 |
| Sunday, January 1, 2017 | 188462000 | 53837297 |
| Monday, January 1, 2018 | 210850000 | 16080096 |
| Tuesday, January 1, 2019 | 240515000 | 18525736 |
| Wednesday, January 1, 2020 | 255497000 | 2024000 |
| Friday, January 1, 2021 | 298182000 | 2548000 |
| Saturday, January 1, 2022 | 349103000 | 61556000 |
| Sunday, January 1, 2023 | 366887000 | 188157000 |
| Monday, January 1, 2024 | 389335000 |
Igniting the spark of knowledge
In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. Bio-Techne Corporation and Telix Pharmaceuticals Limited, two prominent players, showcase contrasting expense trends over the past decade. From 2014 to 2023, Bio-Techne's cost of revenue surged by approximately 266%, reflecting its aggressive growth strategy. In contrast, Telix Pharmaceuticals experienced a more volatile trajectory, with a notable spike in 2023, where costs increased by over 700% compared to 2014. This dramatic rise could indicate strategic investments or scaling challenges. Notably, data for 2024 is incomplete, highlighting the dynamic nature of financial forecasting. As the biotech sector continues to expand, these insights offer a glimpse into the financial health and strategic priorities of these companies. Investors should consider these trends when evaluating potential opportunities in the biotech landscape.
Cost Insights: Breaking Down Eli Lilly and Company and Telix Pharmaceuticals Limited's Expenses
Amgen Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Gilead Sciences, Inc. and Bio-Techne Corporation's Expenses
Analyzing Cost of Revenue: Biogen Inc. and Telix Pharmaceuticals Limited
United Therapeutics Corporation vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Amneal Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Telix Pharmaceuticals Limited vs Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: Telix Pharmaceuticals Limited vs PTC Therapeutics, Inc.
Analyzing Cost of Revenue: Telix Pharmaceuticals Limited and Vericel Corporation
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Wave Life Sciences Ltd.